GMED

Globus MedicalB

NYSE / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$96.00

Analysis reference price unavailable

Analysis 2026-09-19 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$84.00

Analysis reference price unavailable

Analysis 2026-09-19 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$61.00

Analysis reference price unavailable

Analysis 2026-09-19 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-19

AI commentary

Company-specific news tone is moderately positive following the Excelsius3D CE mark and the earlier EPS-guidance increase, but recent coverage is thin. The $74.08 anchor does not establish the market reaction attributable to either event. Social coverage, options skew, short interest, employee ratings and verified analyst revisions are unavailable; zero values denote missing evidence rather than neutral readings. The view remains a fundamentals-led monitoring thesis.

RankAlpha Sentiment Codex - 2026-09-19

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-31eventFull-year 2026 guidance deliveryHigh impact

Globus reaffirmed 2026 revenue guidance of $3.18-$3.22 billion and raised non-GAAP diluted EPS guidance to $4.95-$5.05. Delivery depends on continued spine share gains, margin expansion and synergy realization through year-end. [#SEC-8K-2026-08-06]

2027-08-06catalystSpine share gains and operating leverageHigh impact

Q2 revenue increased 5.9%, while US Spine grew 7%, International Spine grew 14% as reported, and adjusted gross margin expanded 200 basis points. Sustaining those trends would support earnings growth beyond the current guidance period. [#SEC-8K-2026-08-06]

2027-09-03catalystExcelsius3D European commercializationHigh impact

The September 2026 CE mark permits EU and UK commercialization of Excelsius3D, expanding the Excelsius ecosystem through integrated intraoperative imaging and robotic navigation. Hospital adoption and revenue contribution remain unquantified. [#IR-2026-09-03]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-19 • Updated nightlySource: Internal modelMethodology